{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:12:21Z","timestamp":1760278341686,"version":"build-2065373602"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.eplepsyres.2018.09.008","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T19:20:10Z","timestamp":1537644010000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["High incidence of persistent subtherapeutic levels of the most common AEDs in children with epilepsy receiving polytherapy"],"prefix":"10.1016","volume":"148","author":[{"given":"Liliana","family":"Czornyj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"C\u00e1ceres Guido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Bramuglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Rodi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Feria-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Lazarowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0009-9236(96)90192-7","article-title":"The challenge of in-hospital medication use: an opportunity for clinical pharmacology","volume":"60","author":"Atkinson","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.eplepsyres.2018.09.008_bib0010","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00023210-200620100-00001","article-title":"Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?","volume":"20","author":"Adab","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0015","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.farma.2010.10.005","article-title":"Monitorizaci\u00f3n farmacocin\u00e9tica de antiepil\u00e9pticos","volume":"35","author":"Aldaz","year":"2011","journal-title":"Farm Hosp."},{"issue":"2","key":"10.1016\/j.eplepsyres.2018.09.008_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FTD.0b013e318167d11b","article-title":"Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs","volume":"30","author":"Anderson","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4939-3347-1_7","article-title":"Fluorimetric methods for analysis of permeability, drug transport kinetics, and inhibition of the ABCB1 membrane transporter","volume":"1395","author":"Armada","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"38","key":"10.1016\/j.eplepsyres.2018.09.008_bib0030","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.2174\/1381612811319380006","article-title":"P-glycoprotein contributes to cell membrane depolarization of hippocampus and neocortex in a model of repetitive seizures induced by pentylenetetrazole in rats","volume":"19","author":"Auzmendi","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.eplepsyres.2018.09.008_bib0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1528-1167.2010.02573.x","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability","volume":"51","author":"Bialer","year":"2010","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2018.09.008_bib0040","article-title":"ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice","volume":"26","author":"Brzozowska","year":"2016","journal-title":"Peer J."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0045","series-title":"Tratamiento de las Epilpsias","first-page":"103","article-title":"Chapther 3: indicaciones de los f\u00e1rmacos antiepil\u00e9pticos de acuerdo con el tipo de crisis, el tipo de epilepsia o el syndrome epileptic y la etiolog\u00eda","author":"Caraballo","year":"2009"},{"issue":"3\u20134","key":"10.1016\/j.eplepsyres.2018.09.008_bib0050","first-page":"325","article-title":"Evaluating appropriateness of digoxin, carbamazepine, valproic acid, and phenytoin usage by therapeutic drug monitoring","volume":"59","author":"Dalaklioglu","year":"2013","journal-title":"Clin. Lab."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2015.02.025","article-title":"Effect of reduction of antiepileptic drugs in patients with drug-refractory epilepsy","volume":"27","author":"Dash","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0060","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0065","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0070","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/0003-4819-80-4-516","article-title":"Reduction of digoxin toxicity associated with measurement of serum levels: a report from the Boston Collaborative Drug Surveillance program","volume":"80","author":"Duhme","year":"1974","journal-title":"Ann. Intern. Med."},{"issue":"38","key":"10.1016\/j.eplepsyres.2018.09.008_bib0075","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.2174\/13816128113199990368","article-title":"Usefulness of salivary drug monitoring for detecting efflux transporter overexpression","volume":"19","author":"Fagiolino","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1474-4422(13)70109-1","article-title":"P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study","volume":"12","author":"Feldmann","year":"2013","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2018.09.008_bib0085","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.eplepsyres.2018.09.008_bib0090","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0095","series-title":"Antiepileptic Drugs","first-page":"159","article-title":"Phenytoin, chemistry and methods of determination","author":"Glazko","year":"1989"},{"issue":"5","key":"10.1016\/j.eplepsyres.2018.09.008_bib0100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2018.09.008_bib0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/BCR.0b013e3181c89ee3","article-title":"Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis","volume":"31","author":"Hallam","year":"2010","journal-title":"J. Burn Care Res."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neulet.2006.11.075","article-title":"Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model","volume":"413","author":"Hocht","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ijc.2910440126","article-title":"Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multi-drug resistant cells","volume":"44","author":"Hofsli","year":"1989","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.eplepsyres.2018.09.008_bib0120","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bcp.2005.12.033","article-title":"The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells","volume":"71","author":"Holland","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2018.09.008_bib0125","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjp.0707467","article-title":"The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids","volume":"152","author":"Holland","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0130","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1528-1167.2005.59204.x","article-title":"Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus","volume":"46","author":"Iannetti","year":"2005","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2018.09.008_bib0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1590\/S1676-26492010000200006","article-title":"Total, unbound plasma and salivary phenytoin levels in critically ill patients","volume":"16","author":"Ibarra","year":"2010","journal-title":"J. Epilepsy Clin. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bdd.486","article-title":"Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding","volume":"27","author":"Iwamoto","year":"2006","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00606683","article-title":"Disposition of VPA in patients with liver disease","volume":"13","author":"Klotz","year":"1978","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2018.09.008_bib0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archneur.1974.00490410031001","article-title":"Usefulness of blood levels of antiepileptic drugs","volume":"31","author":"Kutt","year":"1974","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0155","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/FTD.0b013e318157032d","volume":"29","author":"Lancelin","year":"2007","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.eplepsyres.2018.09.008_bib0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1528-1157.1991.tb05253.x","article-title":"Plasma antiepileptic drug concentrations during pregnancy","volume":"32","author":"Lander","year":"1991","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0165","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0887-8994(99)00074-0","article-title":"Tuberous sclerosis associated with MDR-1 expression and drug-resistant epilepsy","volume":"21","author":"Lazarowski","year":"1999","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00007691-200402000-00010","article-title":"Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy","volume":"26","author":"Lazarowski","year":"2004","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.eplepsyres.2018.09.008_bib0175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/157488506778194910","article-title":"Multidrug-resistance (MDR) proteins develops refractory epilepsy phenotype: clinical and experimental evidences","volume":"1","author":"Lazarowski","year":"2006","journal-title":"Curr. Drug Ther."},{"issue":"Suppl. 5","key":"10.1016\/j.eplepsyres.2018.09.008_bib0180","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1528-1167.2007.01302.x","article-title":"ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy","volume":"48","author":"Lazarowski","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.eplepsyres.2015.03.007","article-title":"Treatment non-adherence as a trigger for status epilepticus: an observational, retrospective study based on therapeutic drug monitoring","volume":"113","author":"Lie","year":"2015","journal-title":"Epilepsy Res."},{"issue":"8","key":"10.1016\/j.eplepsyres.2018.09.008_bib0190","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.eplepsyres.2018.09.008_bib0195","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.seizure.2007.03.006","article-title":"Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery","volume":"16","author":"Paul","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0205","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00002826-199710000-00008","article-title":"Use of antiepileptic drugs in nontraumatic neurosurgical procedures. Is there any best route and time of administration?","volume":"20","author":"Rabinowicz","year":"1997","journal-title":"Clin. Neuropharmacol."},{"issue":"89","key":"10.1016\/j.eplepsyres.2018.09.008_bib0210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/bdd.728","article-title":"The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results","volume":"31","author":"Ruiz","year":"2010","journal-title":"Biopharm. Drug Dispos."},{"issue":"9","key":"10.1016\/j.eplepsyres.2018.09.008_bib0215","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/WNL.34.9.1252","article-title":"Therapeutic plasma levels of phenytoin, phenobarbital, and carbama-zepine. Individual variation in relation to seizure frequency and type","volume":"34","author":"Schmidt","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.eplepsyres.2018.09.008_bib0220","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.1986.00520030053013","article-title":"The influence of seizure type on the efficacy of plasma concentra-tions of phenytoin, phenobarbital, and carbamazepine","volume":"43","author":"Schmidt","year":"1986","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2018.09.008_bib0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1389200013338595","article-title":"Induction of cytochromes P450","volume":"2","author":"Schuetz","year":"2001","journal-title":"Curr. Drug Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2018.09.008_bib0230","article-title":"Therapeutic drug monitoring beyond","volume":"52","author":"Shenfield","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/157015909788848938","article-title":"Monitoring antiepileptic drugs: a level-headed approach","volume":"7","author":"St. Louis","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0240","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00007691-200206000-00017","article-title":"Evaluation of fluorescence polarization assays for measuringvalproic acid, phenytoin, carbamazepine and phenobarbital in serum","volume":"24","author":"Steijns","year":"2002","journal-title":"Ther. Drug Monit."},{"issue":"301","key":"10.1016\/j.eplepsyres.2018.09.008_bib0245","article-title":"Drug-resistant epilepsy: multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2018.09.008_bib0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1528-1157.1994.tb02921.x","article-title":"Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin","volume":"35","author":"Tomson","year":"1994","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2018.09.008_bib0255","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijantimicag.2012.05.010","article-title":"Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring","volume":"40","author":"Tr\u00f6ger","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.eplepsyres.2018.09.008_bib0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Sub-therapeutic initial \u03b2-lactam concentrations in select critically ill patients","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/jpet.107.121178","article-title":"Region-specific overexpression of P-glycoprotein at the blood brain barrier affects brain uptake of phenytoin in epileptic rats","volume":"322","author":"van Vliet","year":"2007","journal-title":"JPET"},{"issue":"3","key":"10.1016\/j.eplepsyres.2018.09.008_bib0270","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jcrc.2007.11.011","article-title":"Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study","volume":"23","author":"van Zanten","year":"2008","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0275","first-page":"120","article-title":"Increase 99mTc-SESTAMIBI (MIBI) liver clearance could identified epileptic pharmacoresistant patients. A preliminary study","volume":"45","author":"Vazquez","year":"2004","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.eplepsyres.2018.09.008_bib0280","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/17425255.2016.1246536","article-title":"Pharmacotherapy in pediatric epilepsy: rational drug and dose selection","volume":"12","author":"Verrotti","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2018.09.008_bib0285","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10637-009-9340-7","article-title":"Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis","volume":"29","author":"Viale","year":"2011","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0290","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0009-9236(98)90030-3","article-title":"Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein","volume":"64","author":"Wakasugi","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.eplepsyres.2018.09.008_bib0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0300","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/clinchem\/44.5.1085","article-title":"Standards of laboratory practice: antiepileptic drug monitoring","volume":"44","author":"Warner","year":"1998","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.eplepsyres.2018.09.008_bib0305","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: European expert opinion, 2007","volume":"9","author":"Wheless","year":"2007","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0310","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1528-1157.1988.tb04408.x","article-title":"If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study","volume":"29","author":"Woo","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.008_bib0315","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.03.018","article-title":"The prevalence rates of medication adherence and factors influencing adherence to antiepileptic drugs in children with epilepsy: a systematic review and meta analysis","volume":"142","author":"Yang","year":"2018","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.eplepsyres.2018.09.008_bib0320","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.105.098541","article-title":"Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana","volume":"317","author":"Zhu","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118303267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118303267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:40:49Z","timestamp":1760276449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121118303267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":64,"alternative-id":["S0920121118303267"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.09.008","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High incidence of persistent subtherapeutic levels of the most common AEDs in children with epilepsy receiving polytherapy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}